Kolexia
Ajana Faiza Médecine générale
Ajana Faiza
Médecine générale
Hôpital Guy Chatiliez
Tourcoing, France
108 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Infections à VIH Hépatite Hépatite B Insulinorésistance Prise de poids Syndrome métabolique X Toxoplasmose COVID-19 Hépatite A

Collaborateurs

Voir plus
Bocket Laurence
Bocket Laurence
Centre Hospitalier de Lille, Lille, France
Robineau Olivier
Robineau Olivier
Hôpital Guy Chatiliez, Tourcoing, France
Huleux Thomas
Huleux Thomas
Hôpital Bichat-Claude-Bernard, Paris, France
Meybeck Agnes
Meybeck Agnes
Hôpital Guy Chatiliez, Tourcoing, France

Industries

Voir plus
Adliva
9 collaboration(s)
Dernière en 2020
GSK
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2021
Gilead
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ATLAS-2M: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Essai Clinique (ViiV Healthcare)   02 janvier 2024
Delay between primary care access and antiretroviral therapy initiation in the most precarious people living with HIV in Northern France: A monocentric study
HIV medicine Congress 2023   01 décembre 2023
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO): A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Essai Clinique (ViiV Healthcare)   17 juillet 2023
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America   03 octobre 2022
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
The Journal of antimicrobial chemotherapy   29 août 2022
BICOLDER: Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication
Essai Clinique (Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba)   08 juin 2022
Difficulty in reaching viral suppression in a long-term treated HIV-1 patient: Role of the reservoir rather than drug resistance?
Infectious diseases now   11 mars 2022
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
The Journal of antimicrobial chemotherapy   04 mars 2022
Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy.
AIDS (London, England)   01 février 2022
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Journal of acquired immune deficiency syndromes (1999)   17 janvier 2022